Estimated worldwide HIV infections: 54 357 701 as of Thursday October 23 2003.
A flexible new anti-Aids drug, Lexiva, has been approved by the United States’s Food and Drug Administration.
Lexiva, launched by GlaxoSmithKline, is part of a class of drugs known as protease inhibitors that have been manufactured to increase compliance with the drugs. It is said to offer more flexible dosing than similar medicines. According to Glaxo, there are no food and water restrictions, and the two-pill dose can be taken once or twice daily. Other drugs are taken up to eight times daily.
‘It’s important for patients to comply with therapy because current treatment is lifelong,” said Professor Jeffrey P Nadler of the University of South Florida College Of Medicine. ‘Patients need something they can tolerate, so they are able to take the medicines as prescribed. Lexiva fits that picture.”
Glaxo says the drug’s safety and effectiveness was demonstrated in clinical trials involving more than 1 200 people.
Source: http://www.healthday.com